|
|
 |
| |
|
Home > Drug Companies > Wellspring Pharmaceutical Corp.
Wellspring Pharmaceutical Corp.
Important specialty pharmaceutical products are the foundation of their business. While larger pharmaceutical companies are divesting themselves of these unique pharmaceutical products, they recognize their enduring therapeutic value in smaller groups of patients. So they continue to acquire, produce and market a variety of popular, niche products that are used to treat disorders found in neonatology, cancer, and metabolic and cardiovascular diseases.
WellSpring is a privately held company founded in 1999 by Dr. Robert Vukovich. Dr. Vukovich has a long history of success in the pharmaceutical industry. He currently serves as Chief Executive Officer and President of WellSpring. In 1983, Dr. Vukovich founded Roberts Pharmaceutical Corporation, where he served as President and Chief Executive Officer and Executive Chairman until September 1998.
WellSpring Pharmaceuticals is a start up pharmaceutical company with a philosophy of developing and marketing niche products licensed or purchased from major pharmaceutical companies. At WellSpring Pharmaceuticals, they believe no one should be denied the best treatment options.
That's why they develop and market a variety of niche products that are licensed or purchased from the major pharmaceutical companies. WellSpring taps a rich source of excellence that is rooted in decades of world class and breathes new life into widely prescribed drugs with markets below 200 million dollars.
WellSpring offers a line of specialty branded pharmaceutical products focusing on cardiovascular and endocrine diseases. Its strategic focus is on four therapeutic areas: neonatology, oncology, endocrinology, and cardiology. The company is currently working with major multinational pharmaceutical organizations to acquire low volume niche products.
WellSpring Pharmaceuticals is focused on establishing itself as a high profile, quality provider of unique, niche pharmaceuticals in four therapeutic areas neonatology, oncology, endocrinology and cardiology.
WellSping will continue to acquire new products for commercialization. Several promising, novel candidates have been identified and the company is progressing toward such acquisitions. The objective of the company is to develop late stage, patented drugs intended for specialty or niche markets. The intent is to self fund the development of these products from revenues generated by product sales.
Back to Drug Companies
|
|
|
|
|
|
|
|